NCT07610798

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: RECRUITING

Phase: PHASE1, PHASE2

Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.

Condition: Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic, Ovarian Cancer, Endometrial Cancer, Biliary Cancers

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: None

Results signal: Low Signal

Operational burden: few_sites_large_trial_signal | rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.